膀胱癌黏膜下注射度伐利尤单抗的I期剂量递增试验方案(SUBDUE-1)
SUBDUE-1是一项I期开放标签剂量递增试验,评估肌层浸润性或高危非肌层浸润性膀胱癌成人患者黏膜下注射度伐利尤单抗的耐受性、安全性和免疫学疗效。主要目标是评估安全性与耐受性,次要目标为局部免疫学疗效。
要点
- 研究三种固定总剂量度伐利尤单抗(25、75、150 mg)以确定II期试验适用剂量。
- 主要终点为不良事件发生率和严重程度及剂量限制性毒性。
- 次要疗效终点包括切除时pT0率、淋巴结状态及肿瘤浸润淋巴细胞和肿瘤激活巨噬细胞分布变化。
核心结论
- 若证实安全有效,黏膜下注射度伐利尤单抗可能为高危NMIBC或BCG难治性NMIBC患者提供减少肿瘤复发和进展的额外治疗选择。
- 局部给药度伐利尤单抗可能比全身给药减少免疫相关副作用并降低成本。
研究设计与样本
- I期开放标签剂量递增试验,纳入计划行根治性膀胱切除术或拒绝/不适合全身新辅助化疗的高危NMIBC或MIBC成人患者。
- 研究三种固定总剂量度伐利尤单抗(25、75、150 mg),以确定适合推进至II期试验的剂量。
关键数值与推荐
- 主要终点:通过患者报告结局指标及观察到的局部或全身不良事件评估黏膜下注射度伐利尤单抗的安全性。
- 次要疗效终点:切除时pT0率、淋巴结状态、注射前后膀胱活检中肿瘤浸润淋巴细胞和肿瘤激活巨噬细胞分布变化。
- 转化研究聚焦膀胱肿瘤分子亚型、免疫浸润特征和免疫检查点蛋白表达与疗效终点的关系。
临床怎么用
- 该方案为高危NMIBC或MIBC患者提供局部免疫治疗的新策略,旨在促进抗肿瘤免疫反应。
- 局部给药可能减少免疫相关副作用并降低费用,但需待试验结果验证。
局限性
- 本文为试验方案,尚无安全性或疗效结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This article presents the clinical trial protocol for a phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (NMIBC), the SUB-urothelial DUrvalumab injection-1 study (SUBDUE-1). The primary objectives of this study are to assess the safety of sub-urothelial injection of durvalumab using patient reported outcome measures and observed local or systemic adverse events. The secondary objectives are to examine the local immunological efficacy of sub-urothelial administration of durvalumab. PATIENTS AND METHODS: The SUBDUE-1 trial will include adult patients with either high-risk NMIBC or MIBC, who are scheduled for radical cystectomy or who have refused or are unsuitable for systemic neoadjuvant chemotherapy. Three fixed total dose levels of durvalumab (25, 75, 150 mg) will be studied to identify a dose suitable to be taken forward into phase II trials. The primary endpoint is to evaluate the safety and tolerability of the trial intervention in terms of the incidence and severity of adverse events and the potential establishment of dose-limiting toxicities. The secondary efficacy endpoints include rates of pT0 status at resection, lymph node status, as well as the change in distribution of tumour-infiltrating lymphocytes and tumour-activated macrophages between pre- and post-injection bladder biopsies. Translational studies will focus on bladder tumour molecular sub-typing, immune infiltrate characterisation, and immune checkpoint protein expression relative to efficacy end-points. OUTCOME AND SIGNIFICANCE: If proven safe and effective, this novel strategy comprising sub-urothelial durvalumab injections aimed at promoting an anti-tumour immune reaction, will provide additional treatment options for reducing tumour recurrence and progression in treatment-naïve patients with high-risk NMIBC or in patients with bacille Calmette-Guérin-refractory NMIBC. Local administration of durvalumab may be associated with a reduced rate of immunological side-effects and lower costs when compared to systemic delivery.
引用
- Moe A, Liow E, Redfern A, et al. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol. BJU Int. 2021. PMID: 33960102. doi:10.1111/bju.15365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。